Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

3 results
11:32 AM, Jan 20, 2017  |  BC Week In Review | Company News  |  Deals

APT Therapeutics, AZ deal

The companies partnered to develop APT's APT102 . APT will receive an upfront payment and is …
development milestones. AstraZeneca, which has an option to acquire the product, will fund trials of APT102
to treat heart attack and stroke. APT102, a recombinant form of human apyrase, is in preclinical …
12:00 AM, Sep 11, 2014  |  BC Innovations | Distillery Therapeutics

Indication: Cardiovascular disease

can be broken down by the apyrase activity of ENTPD3. An optimized version of ENTPD3-called APT102-was …
that showed reduced aggregation and increased apyrase activity compared with the natural protein. In vitro, APT102
ADP-dependent human platelet aggregation. In a canine model of thrombotic occlusion of the coronary artery, APT102
12:00 AM, May 10, 2004  |  BioCentury | Finance

Midwest work ethic

will provide about two years of runway and allow it to submit INDs for its APT102